跳至主要内容
临床试验/PER-035-11
PER-035-11未知未知

A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 2 STUDY OF THE SAFETY/ TOLERABILITY AND EFFICACY OF JNJ-32729463 COMPARED WITH MOXIFLOXACIN FOR THE TREATMENT OF SUBJECTS REQUIRING HOSPITALIZATION FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) WITH A PORT SCORE OF II OR GREATER

FURIEX PHARMACEUTICALS, INC,0 个研究点目标入组 0 人开始时间: 2011年8月3日最近更新:

试验速览

阶段
未知

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 75(—)

入选标准

  • 1. SUBJECT IS MALE OR FEMALE BETWEEN THE AGE OF 18 AND 85 YEARS, INCLUSIVE.
  • 2. IF THE SUBJECT IS FENALE AND OF CHILDBEARING POTENTIAL, THE SUBJECT AGREES TO USE AN ACCEPTABLE FORM OF CONTRACEPTION. ACCEPTABLE FORMS OF CONTRACEPTION FOR SUBJECT OR PARTNER INCLUDE CONDOMS WITH SPERMICIDE GEL, DIAPHRAGM WITH SPERMICIDE GEL, COIL (INTRAUTERINE DEVICE), SURGICAL STERILIZATION, VASECTOMY, ORAL CONTRACEPTIVE PILL, DEPOT PROGESTERONE INJECTIONS, AND ABSTINENCE.
  • 3. SUBJECTS HAS CABP REQUIRING HOSPITALIZATION WITH A PORTH SCORE OF II OR GREATER (APPENDIX 3).
  • 4. SUBJECT HAS 3 OR MORE OF THE FOLLOWING CLINICAL SIGNS AND SYMPTOMS:
  • A. COUGH WITH PRODUCTION OF PURULENT SPUTUM
  • B. DYSPNEA OR TACHYPNEA
  • C. CHEST PAIN
  • D. FEVER OR HYPOTHERMIA:
  • I. FEVER IS DEFINED AS BODY TEMPERATURE > 38°C (I00.4°F) TAKEN ORALLY, > 38.5°C (101.3 °F) TYMPANICALLY, OR> 39°C (102.2°F) RECTALLY.
  • II. HYPOTHERMIA IS DEFINED AS BODY TEMPERATURE <35°C (95°F).
  • E. CLINICAL FINDINGS OF PULMONARY CONSOLIDATION (eg, DULLNESS ON PERCUSSION, BRONCHIAL BREATH SOUNDS, OR EGOPHONY)
  • 5. SUBJECT´S CHEST X-RAY SHOWS THE PRESENCE OF NEW INFILTRATES IN A LOBAR OR MULTILOBULAR DISTRIBUTION CHARACTERISTIC OB BACTERIAL PNEUMONIA. SUBJECTS WITH THE PRESENCE OF NECROTIZING LESIONS CHARACTERITIC OF S. AUREUS PNEUMONIA ARE ELIGIBLE FOR ENROLLMENT IN THE OPEN-LABEL JNJ-32729463 TREATMENT ARM FOR S. AUREUS PNEUMONIA.

排除标准

  • 1. SUBJECT IS INTUBATED AT THE TIME OF CONSENT OR SUBJECT IS A CANDIDATE FOR ENROLLMENT INTO THE OPEN-LABEL TREATMENT S. AUREUS ARM AND HAS BEEN INTUBATED GREATER THAN 12 HOURS PRIOR TO RANDOMIZATION. (THIS DOES NOT EXCLUDE SUBJECTS WHO REQUIRE POSITIVE-PRESSURE BREATHING, SUCH AS CONTINUOUS POSITIVE AIRWAY PRESSURE OR BILEVEL POSITIVE AIRWAY PRESSURE. ALSO, PATIENTS WHO REQUIRE INTUBATION AFTER RANDOMIZATION MAY REMAIN IN THE STUDY).
  • 2. SUBJECTS HAS MILD CABP WITH A PORT SCORE OF LESS THAN II.
  • 3. THE PATIENT HAS RECEIVED ANY SYSTEMIC ANTIBIOTIC IN THE LAST 96 HOURS BEFORE THE RANDOMIZATION, UNLESS:
  • A. BE PATIENT HIV NEGATIVE AND HAVE RECEIVED TREATMENT FOR RESPIRATORY INFECTION WITH ANY ANTIBIOTIC, A FLUOROQUINOLONE EXCEPT FOR A COURSE OF TREATMENT> 48 HOURS AND <6 DAYS, AND GATHER THE CLINICAL FAILURE FOLLOWING CRITERIA:
  • I. THE GRAM STAIN SAMPLE SPUTUM LESS THAN 10 SQUAMOUS EPITHELIAL CELLS AND POLYMORPHONUCLEAR CELLS OVER 25 FOR LOW POWER FIELD (100X MAGNIFICATION) AND MICRO PREDOMINANT L0 LEAST 1 NBAC CONSISTENT WITH, AND
  • II.THE PATIENT AT LEAST ONE OF THE FOLLOWING:
  • 1)ADVANCE NBAC SYMPTOMS
  • 2)SYMPTOM DEVELOPMENT NEW / ADDITIONAL NBAC
  • 3)DEVELOPMENT OF NEW DISCOVERIES / ADDITIONAL IN CHEST RADIOGRAPHY WITH CONSEQUENTIAL NBAC.

研究者

相似试验

进行中(未招募)
1 期
Clinical trial to investigate safety and efficacy of an Omega-3-fatty acid triglycerides (fish-oil”) enriched lipid emulsion in comparison to a lipid emulsion not containing fish-oil” in home parenteral nutrition in adults
EUCTR2015-000849-23-NLB. Braun Melsungen AG160
已完成
4 期
A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSIOchronic bowel failurechronic intestinal failure10025477
NL-OMON55393B.Braun Melsungen AG25
进行中(未招募)
1 期
Clinical trial to investigate safety and efficacy of an Omega-3-fatty acid triglycerides (fish-oil”) enriched lipid emulsion in comparison to a lipid emulsion not containing fish-oil” in home parenteral nutrition in adultsChronic intestinal failureMedDRA version: 20.0 Level: SOC Classification code 10017947 Term: Gastrointestinal disorders System Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2015-000849-23-GBB. Braun Melsungen AG160
进行中(未招募)
不适用
A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN CORTICOSTEROID-DEPENDENT ULCERATIVE COLITIS - METEORSteroid-dependent ulcerative colitis
EUCTR2006-003607-40-BEBesancon University Hospital110
进行中(未招募)
不适用
A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN STEROID-REFRACTORY ULCERATIVE COLITIS - METEOR
EUCTR2006-003607-40-NLBesancon University Hospital110
A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER,... | 临床试验